Alkem Laboratories Ltd

Profit before exceptional items and tax jumped 40.74% YoY to Rs 557.82 crore in Q4 FY26. Exceptional items for the quarter include Rs 60.27 crore incremental liablitiy towards gratuity and leave enchasehment for past service cost following finalization of central rules under labour codes and Rs 74.7 crore towards impairment of real estate investments. EBITDA stood at Rs 517.4 crore in Q4 FY26, up 32.2% YoY. EBITDA margin improved to 14.4% in Q4 FY26 as against 12.4% in Q4 FY25. During the quarter, R&D expenses stood at Rs 229.3 crore, up 44.67% compared with Rs 158.5 crore in Q4 FY25 and accounted for 6.4% of total revenue. India sales were Rs 2,324.5 crore in Q4 FY26, YoY growth of 8.8%. International sales stood at Rs 1,222.3 crore, up 25.4% YoY. On an annual basis, the company's consolidated net profit rose 6.3% to Rs 2,301.80 crore in FY26 compared with Rs 2,165.48 crore in FY25. Revenue from operations jumped 13.48% to Rs 14,712.27 crore in FY26 compared with Rs 12,964.52 crore in FY25. Vikas Gupta, CEO of Alkem, said, 'We are pleased to report that Alkem has recorded its highest ever EBIDTA in FY26, reaffirming the strength of our growth strategy, execution and operational rigour. Our top-line growth was broad-based with both domestic branded generics and international business delivering strong growth. An improving business mix, operating leverage and continued cost discipline drove meaningful margin expansion in FY26. Our financial performance in Q4 was also marked by strong revenue and EBITDA growth as well as a significant increase of 40.7% in our profit before tax and exceptional item. We enter FY27 on a firm foundation and expect healthy growth across businesses supported by increasing contribution from chronic therapies and a differentiated launch pipeline for international markets.' Meanwhile, the company's board recommended a final dividend of Rs 10 per equity share of Rs 2 each for financial year ended 31st March, 2026. The company fixed record date as 7th August, 2026 for final dividend. It will be paid on and from 1st September 2026. Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products.Powered by Capital Market - Live

Stocks to Watch: Wipro expanded its partnership with ServiceNow to implement and scale the impact of agentic AI workflows across core enterprise functions such as IT, HR, procurement, and cybersecurity. Under this expanded partnership, Wipro will integrate Wipro Intelligence, its unified suite of AI-powered platforms, solutions, and transformative offerings, with the ServiceNow AI Platform enabling organizations to streamline the initiation, orchestration, and execution of work across enterprise systems. Alkem Laboratories reported 25.11% drop in consolidated net profit to Rs 251.11 crore despite 14.62% jump in revenue from operations to Rs 3,603.32 crore in Q4 March 2026 over Q4 March 2025. Roto Pumps reported a 55.47% decline in consolidated net profit to Rs 5.73 crore in the quarter ended 31 March 2026, compared with Rs 12.87 crore posted in the corresponding quarter last year. PC Jeweller reported 58.06% jump in standalone net profit to Rs 150.33 crore on 32.66% increase in revenue from operations to Rs 927.34 crore in Q4 FY26 over Q4 FY25. PG Electroplast reported 55.34% decline in consolidated net profit to Rs 64.86 crore in Q4 FY26 compared with Rs 145.23 crore posted in Q4 FY25. Revenue from operations dropped 10.11% YoY to Rs 1,716.67 crore in Q4 FY26. Time Technoplast has reported 20.4% rise in consolidated net profit to Rs 131.84 crore on a 14.2% increase in revenue from operations to Rs 1,676.67 crore in Q4 FY26 over Q4 FY25. Axiscades Technologies has reported 98.6% drop in consolidated net profit to Rs 0.43 crore in Q4 FY26 from Rs 30.76 crore in Q4 FY25. Revenue for the period under review rose by 1.9% year-on-year (YoY) to Rs 273.01 crore during the period under review. Gulf Oil Lubricants India has reported 3.44% drop in consolidated net profit to Rs 89.59 crore despite a 10.76% increase in revenue from operations to Rs 1,055.26 crore in Q4 FY26 over Q4 FY25.Powered by Capital Market - Live

Net profit of Alkem Laboratories declined 22.69% to Rs 236.46 crore in the quarter ended March 2026 as against Rs 305.86 crore during the previous quarter ended March 2025. Sales rose 14.62% to Rs 3603.32 crore in the quarter ended March 2026 as against Rs 3143.75 crore during the previous quarter ended March 2025. For the full year,net profit rose 6.30% to Rs 2301.80 crore in the year ended March 2026 as against Rs 2165.48 crore during the previous year ended March 2025. Sales rose 13.48% to Rs 14712.27 crore in the year ended March 2026 as against Rs 12964.52 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales3603.323143.75 15 14712.2712964.52 13 OPM %14.3612.45 -20.4319.38 - PBDT663.58508.83 30 3427.782884.19 19 PBT557.82396.34 41 3045.722527.03 21 NP236.46305.86 -23 2301.802165.48 6 Powered by Capital Market - Live

Alkem Laboratories announced that the Board of Directors of the Company at its meeting held on 28 May 2026, inter alia, have recommended the final dividend of Rs 10 per equity Share (i.e. 500%) , subject to the approval of the shareholders.

Profit before exceptional items and tax jumped 40.74% YoY to Rs 557.82 crore in Q4 FY26. Exceptional items for the quarter include Rs 60.27 crore incremental liablitiy towards gratuity and leave enchasehment for past service cost following finalization of central rules under labour codes and Rs 74.7 crore impairment of real estate investments. EBITDA stood at Rs 517.4 crore in Q4 FY26, up 32.2% YoY. EBITDA margin improved to 14.4% in Q4 FY26 as against 12.4% in Q4 FY25. During the quarter, R&D expenses stood at Rs 229.3 crore compared with Rs 158.5 crore in Q4 FY25 and accounted for 6.4% of total revenue. India sales were Rs 2,324.5 crore in Q4 FY26, YoY growth of 8.8%. International sales stood at Rs 1,222.3 crore, up 25.4% YoY. On annual basis, the company's consolidated net profit rose 6.3% to Rs 2,301.80 crore in FY26 compared with Rs 2,165.48 crore in FY25. Revenue from operations jumped 13.48% to Rs 14,712.27 crore in FY26 compared with Rs 12,964.52 crore in FY25. Vikas Gupta, CEO of Alkem, said, 'We are pleased to report that Alkem has recorded its highest ever EBIDTA in FY26, reaffirming the strength of our growth strategy, execution and operational rigour. Our top-line growth was broad-based with both domestic branded generics and international business delivering strong growth. An improving business mix, operating leverage and continued cost discipline drove meaningful margin expansion in FY26. Our financial performance in Q4 was also marked by strong revenue and EBITDA growth as well as a significant increase of 40.7% in our profit before tax and exceptional item. We enter FY27 on a firm foundation and expect healthy growth across businesses supported by increasing contribution from chronic therapies and a differentiated launch pipeline for international markets.' Meanwhile, the company's board recommended a final dividend of Rs 10 per equity share of Rs 2 each for financial year ended 31 st March, 2026. The company fixed record date as 7th August, 2026 for final dividend. It will be paid on and from 1st September 2026. Alkem Laboratories is engaged in the pharmaceutical business with global operations. The company is engaged in the development, manufacture, and sale of pharmaceutical and nutraceutical products. Th counter advanced 1.36% to end at Rs 5,452.25 on the BSE. The stock market remained closed today on account of Bakri Id.Powered by Capital Market - Live

Alkem Laboratories will hold a meeting of the Board of Directors of the Company on 28 May 2026.

Alkem Laboratories announced the appointment of Chanakya Misra into a senior management position in the company effective from 18 May 2026.

Alkem Laboratories announced that the USFDA conducted an unannounced inspection on 08 May 2026 at the company' CRO facility located at Taloja, Maharashtra. At the end of the inspection, no form 483 was issued.

Alkem Laboratories announced the incorporation of a wholly owned subsidiary in the name of Alkem Pharma Trading FZCO in Dubai, UAE. The subsidiary will undertake export of company's products to African, South East Asian and non-UAE markets.

Alkem Laboratories Ltd gained for a third straight session today. The stock is quoting at Rs 5428.5, up 1.08% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.99% on the day, quoting at 24011.35. The Sensex is at 77413.31, up 1.02%. Alkem Laboratories Ltd has slipped around 2.09% in last one month. Meanwhile, Nifty Pharma index of which Alkem Laboratories Ltd is a constituent, has slipped around 5.16% in last one month and is currently quoting at 22135.4, up 0.04% on the day. The volume in the stock stood at 34997 shares today, compared to the daily average of 1.27 lakh shares in last one month. The benchmark April futures contract for the stock is quoting at Rs 5438.5, up 0.72% on the day. Alkem Laboratories Ltd is up 11.07% in last one year as compared to a 5.18% spurt in NIFTY and a 8.22% spurt in the Nifty Pharma index.The PE of the stock is 29 based on TTM earnings ending December 25.